Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease

Journal of Neural Transmission

Volumn 119, Issue 7, 2012, Pages 799-804

  Vlachos, George S ^a   Paraskevas, George P ^a   Naoumis, Dimitris ^a   Kapaki, Elizabeth ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Alzheimer's disease; Amyloid beta; Biomarkers; Cerebrospinal fluid; Rapid progression

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THREONINE;

ALZHEIMER DISEASE; ANALYSIS OF COVARIANCE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARAMETERS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TAU PROTEINS; TIME FACTORS;

EID: 84863454433     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0798-7     Document Type: Article

References (37)

1. Bian H, Grossman M (2007) Frontotemporal lobar degeneration: recent progress in antemortem diagnosis. Acta Neuropathol 114(1):23-29. doi:10.1007/s00401-007-0235-4
2. Capitani E, Cazzaniga R, Francescani A, Spinnler H (2004) Cognitive deterioration in Alzheimer's disease: is the early course predictive of the later stages? Neurol Sci 25(4):198-204. doi: 10.1007/s10072-004-0322-4
3. Caselli RJ, Beach TG, Yaari R, Reiman EM (2006) Alzheimer's disease a century later. J Clin Psychiatry 67(11):1784-1800
4. Castellani RJ, Lee HG, Siedlak SL, Nunomura A, Hayashi T, Nakamura M, Zhu X, Perry G, Smith MA (2009) eexamining Alzheimer's disease: evidence for a protective role for amyloidbeta protein precursor and amyloid-beta. J Alzheimers Dis 18(2):447-452. doi:GP32KR168311422510.3233/JAD-2009-1151
5. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDSADRDA criteria. Lancet Neurol 6(8):734-746. doi:S1474-4422(07)70178-310. 1016/S1474-4422(07)70178-3
6. Dumont C, Voisin T, Nourhashemi F, Andrieu S, Koning M, Vellas B (2005) Predictive factors for rapid loss on the mini-mental state examination in Alzheimer's disease. J Nutr Health Aging 9(3):163-167
7. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503): 2112-2117. doi:S0140-6736(05)67889-010.1016/S0140-6736(05) 67889-0
8. Forman MS, Trojanowski JQ, Lee VM (2004) Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 10(10):1055-1063. doi:10.1038/nm1113nm1113
9. Gauthier S, Vellas B, Farlow M, Burn D (2006) Aggressive course of disease in dementia. Alzheimers Dement 2(3):210-217. doi: S1552-5260(06)00049- 510.1016/j.jalz.2006.03.002
10. Haldenwanger A, Eling P, Kastrup A, Hildebrandt H (2010) Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease. J Alzheimers Dis 22(3):971-980. doi: B0433631X0403W7710.3233/JAD-2010-101203
11. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K (2004) Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 9(7):705-710. doi:10.1038/sj.mp. 40014734001473
12. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K (2010) Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 223(2):334-346. doi:S0014-4886(09)00411-710. 1016/j.expneurol.2009.09.024
13. Han L, Cole M, Bellavance F, McCusker J, Primeau F (2000) Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr 12(2):231-247
14. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis. doi:1VP33GJ83708777R10. 3233/JAD-2010-100207
15. Herukka SK, HallikainenM, Soininen H, Pirttila T (2005) CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64(7):1294-1297. doi:64/7/129410.1212/01.WNL.0000156914. 16988.56
16. Kapaki E, Paraskevas GP, Zalonis I, Zournas C (2003) CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the greek population. Eur J Neurol 10(2):119-128. doi:562
17. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73(17):1353-1358. doi:73/17/135310.1212/ WNL.0b013e3181bd8271
18. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75(3):230-238. doi:WNL.0b013e3181e8e8b810.1212/WNL.0b013e3181e8e8b8
19. Locascio JJ, Fukumoto H, Yap L, Bottiglieri T, Growdon JH, Hyman BT, Irizarry MC (2008) Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol 65(6):776-785. doi:65/6/77610.1001/archneur.65.6.776
20. Lublin AL, Gandy S (2010) Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med 77(1):43-49. doi:10.1002/msj.20160
21. Mattsson N, Blennow K, Zetterberg H (2009) CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci 1180:28-35. doi:NYAS494410.1111/j.1749- 6632.2009.04944.x
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34(7):939-944
23. Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R et al (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38(4):643-648. doi:10.1002/ana.410380413
24. Paraskevas GP, Kapaki E, Liappas I, Theotoka I, Mamali I, Zournas C, Lykouras L (2005) The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders. J Geriatr Psychiatry Neurol 18(3):163-173. doi: 18/3/16310.1177/0891988705277549
25. Paraskevas GP, Kapaki E, Papageorgiou SG, Kalfakis N, Andreadou E, Zalonis I, Vassilopoulos D (2009) CSF biomarker profile and diagnostic value in vascular dementia. Eur J Neurol 16(2):205-211. doi:ENE238710.1111/j.1468-1331. 2008.02387.x
26. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW (2010) Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74(3):201-209. doi:WNL.0b013e3181cb3e2510.1212/WNL.0b013e3181cb3e25
27. Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC (2011) Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 49(9):2384-2390. doi:S0028-3932(11)00198-910.1016/j. neuropsychologia.2011.04.012
28. Qiu C, De Ronchi D, Fratiglioni L (2007) The epidemiology of the dementias: an update. Curr Opin Psychiatry 20(4):380-385. doi: 10.1097/YCO.0b013e32816ebc7b00001504-200707000-00012
29. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I (2011) Rapidly progressive Alzheimer disease. Arch Neurol 68(9):1124-1130. doi:68/9/112410. 1001/archneurol.2011.189
30. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C (2010) CSF amyloid beta 1-42 predicts cognitive decline in Parkinson disease. Neurology 75(12):1055-1061. doi:WNL.0b013e3181f39a7810.1212/WNL.0b013e3181f39a78
31. Sona A, Zhang P, Ames D, Bush AI, Lautenschlager NT, Martins RN, Masters CL, Rowe CC, Szoeke C, Taddei K, Ellis KA (2012) Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr 24(2):197-204. doi: S104161021100133510.1017/S1041610211001335
32. Soto C, Estrada LD (2008) Protein misfolding and neurodegeneration. Arch Neurol 65(2):184-189. doi:65/2/18410.1001/archneurol.2007.56
33. Soto ME, Andrieu S, Arbus C, Ceccaldi M, Couratier P, Dantoine T, Dartigues JF, Gillette-Guyonnet S, Nourhashemi F, Ousset PJ, Poncet M, Portet F, Touchon J, Vellas B (2008) Rapid cognitive decline in Alzheimer's disease. Consensus paper. J Nutr Health Aging 12(10):703-713
34. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins PV, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG (2011) Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry 19(6):532-542. doi:10.1097/JGP.0b013e3181faec2300019442-201106000-00005
35. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfelt L, Mehta PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46(Pt 3):235-240. doi: acb.2009.00823210.1258/acb.2009.008232
36. Wallin AK, Blennow K, Andreasen N, Minthon L (2006) CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 21(3):131-138. doi:DEM200602100313110.1159/000090631
37. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74(19):1531-1537.doi:74/19/153110.1212/WNL.0b013e3181dd4dd8